Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 27;21(12):56.
doi: 10.1007/s11934-020-01009-7.

Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED

A Sebastianelli  1   2 , P Spatafora  1   2 , S Morselli  1   2 , L Vignozzi  3 , S Serni  1   2 , K T McVary  4 , S Kaplan  5 , S Gravas  6 , C Chapple  7 , Mauro Gacci  8   9
Affiliations
Review

Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED

A Sebastianelli et al. Curr Urol Rep. .

Abstract

Purpose of review: Aim of our systematic review is to evaluate and summarize the efficacy and safety of tadalafil alone or in combination with tamsulosin for the management of lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) and erectile dysfunction (ED).

Recent findings: Daily tadalafil, in particular 5 mg, according to retrieved studies, appears to be both safe and effective in treating LUTS/BPH and ED, compared with placebo or tamsulosin. The combination of daily tadalafil 5 mg and tamsulosin 0.4 mg allows a better improvement of LUTS compared with both the monotherapies, even if with an increased, but acceptable and tolerated, adverse events rate. After discontinuation of tamsulosin or tadalafil in patients previously treated with their combination, the improvement of LUTS retains significance compared with baseline. Tadalafil 5 mg should be considered a primary treatment option for patients with LUTS/BPH and ED. Evidence highlight an excellent tolerability, safety, and effectiveness profile, both alone or in combination with tamsulosin 0.4 mg. A better efficacy on LUTS relief has been observed for combination therapy, preserving also sexual function. The further switch to monotherapy allows to preserve LUTS relief, but tadalafil only is able to retain ED improvement. Our results support the evidence for a more and more tailored and modular LUTS treatment.

Keywords: Benign prostatic hyperplasia; Combination therapy; Erectile dysfunction; Lower urinary tract symptoms; Tadalafil; Tamsulosin.

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest from any authors.

Figures

Fig. 1
Fig. 1
Flow diagram of literature searches according to PRISMA statement
See this image and copyright information in PMC

References

    1. Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011;60(4):809–825. doi: 10.1016/j.eururo.2011.06.037. - DOI - PubMed
    1. Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, et al. Management of non-neurogenic male LUTS. In: EAU Guidelines 2020. Arnhem, The Netherlands: EAU Guidelines Office; 2020. Available from: https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/.
    1. Mirone V, Sessa A, Giuliano F, Berges R, Kirby M, Moncada I. Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events. Int J Clin Pract. 2011;65(9):1005–1013. doi: 10.1111/j.1742-1241.2011.02731.x. - DOI - PubMed
    1. Giuliano F, Uckert S, Maggi M, Birder L, Kissel J, Viktrup L. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol. 2013;63(3):506–516. doi: 10.1016/j.eururo.2012.09.006. - DOI - PubMed
    1. Morelli A, Sarchielli E, Comeglio P, Filippi S, Mancina R, Gacci M, Vignozzi L, Carini M, Vannelli GB, Maggi M. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med. 2011;8(10):2746–2760. doi: 10.1111/j.1743-6109.2011.02416.x. - DOI - PubMed

MeSH terms